DelveInsight’s “Shingles Pipeline Insight, 2026” report delivers comprehensive insights about 18+ companies developing 20+ pipeline drugs in the Shingles pipeline landscape. It encompasses the Shingles pipeline drug profiles, including clinical and nonclinical stage products, along with therapeutics assessment by product type, stage, route of administration, and molecule type, and further highlights inactive pipeline products in this space.
Explore the latest breakthroughs in the Shingles treatment landscape. Discover more about the evolving Shingles pipeline today @ https://www.delveinsight.com/sample-request/shingles-pipeline-insight
Key Highlights from the Shingles Pipeline Report
- In April 2026, the University of Colorado, Denver launched a clinical trial to assess the efficacy and safety of the Shingrix vaccine in adults with kidney failure awaiting or receiving transplants.
- In March 2026, MAXVAX Biotechnology announced Phase III clinical trials to assess the protective efficacy of its Recombinant Herpes Zoster Vaccine (CHO Cell) in preventing shingles.
- In January 2026, Curevo Vaccine announced favorable Phase 2 data for its candidate Amezosvatein (CRV-101), showing non-inferior immune response to Shingrix with enhanced tolerability.
- Shingles, or Herpes Zoster, results from the reactivation of the latent varicella-zoster virus (VZV), with risk increasing alongside age-related immune system decline.
- DelveInsight’s Shingles Pipeline report illustrates a robust clinical development space with 18+ active players advancing 20+ pipeline therapies for treatment across multiple stages.
- The recombinant vaccine segment is projected to increase its market share from 75% in 2024 to over 95% by 2028, largely replacing lower-cost live vaccine alternatives.
- Prominent Shingles companies include Zhuhai Trinomab Pharmaceutical, Nobelpharma, Dynavax Technologies, Jiangsu Rec-Biotechnology, Moderna, Curevo, Amytrx Therapeutics, among others.
- Investigational therapies in development include Amezosvatein (CRV-101), REC610, LZ901, and GNW002, spanning recombinant proteins, mRNA, and monoclonal antibodies.
Download for updates and the latest revolution in Shingles care @ https://www.delveinsight.com/sample-request/shingles-pipeline-insight
Shingles Emerging Drugs Profile
- Amezosvatein (CRV-101): Curevo Vaccine
Amezosvatein is an investigational non-mRNA adjuvanted subunit vaccine targeting glycoprotein E (gE) for the prevention of shingles. It was specifically engineered to produce an optimal immune response while improving tolerability compared to current standards. Recent Phase 2 data announced in January 2026 confirmed its non-inferior immune response and strong safety profile. Currently, the drug is in Phase II clinical evaluation for the treatment of Shingles.
- REC610: Jiangsu Recbio Technology
REC610 is a novel adjuvanted recombinant zoster vaccine that has demonstrated a positive safety profile in Phase I trials in healthy participants aged 40 and above. The vaccine induces strong gE-specific humoral and cellular immune responses, which peak 30 days after the second dose. Recbio received clinical trial approval from the NMPA in late 2023. Currently, REC610 is in Phase I clinical trial evaluation for the treatment of Shingles.
- LZ901: Beijing Luzhu Biotechnology
LZ901 is the first global zoster vaccine candidate featuring a tetrameric molecular structure in an Fc fusion protein format. It utilizes gE-Fc fusion proteins as antigens and is adjuvanted with aluminum. The tetrameric structure is designed to boost immune responses beyond benchmarks set by existing recombinant vaccines. Currently, LZ901 is advancing through clinical development stages for Shingles treatment.
For more information on the Shingles Emerging Drugs Profile, download https://www.delveinsight.com/sample-request/shingles-pipeline-insight
The Shingles Pipeline Report Delivers
- Detailed insights about companies developing therapies for Shingles, with aggregate therapies developed by each company.
- Various therapeutic candidates, segmented into early-stage, mid-stage, and late-stage of development for Shingles treatment.
- Shingles companies that are engaged in targeted therapeutics development with respective active and inactive projects.
- Shingles drugs under development categorized by stage, route of administration, mechanism of action, and molecular type.
- Comprehensive analysis of collaborations, licensing agreements, and financing details for future advancement of the Shingles market.
Discover more about Shingles drug opportunities in our comprehensive Shingles pipeline report @ https://www.delveinsight.com/sample-request/shingles-pipeline-insight
Shingles Companies and Competitive Landscape
There are 18+ key companies, including GlaxoSmithKline, Merck, Moderna, Curevo, Zhuhai Trinomab, Nobelpharma, among others, developing therapies for Shingles, with a major focus on proactive prevention through recombinant and mRNA-based vaccines.
DelveInsight’s Shingles pipeline report delivers the therapeutic assessment of the pipeline drugs by Route of Administration. Products have been categorized under various ROAs such as:
- Oral
- Intravenous
- Parenteral
- Subcutaneous
- Topical
Shingles products have been categorized under various Molecule types such as:
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Explore the latest advancements in Shingles treatment by visiting our website. Stay informed @ https://www.delveinsight.com/sample-request/shingles-pipeline-insight\
Scope of the Shingles Pipeline Report
- Coverage: Global
- Shingles Companies: Zhuhai Trinomab Pharmaceutical, Nobelpharma, Dynavax Technologies, Rec-Bio, Moderna, Curevo, Amytrx Therapeutics, GSK, Merck, Pfizer, Sanofi, Novartis, among others.
- Shingles Therapies: Amezosvatein (CRV-101), REC610, LZ901, GNW002, Z-1018, EPB-348, and other undisclosed pipeline candidates.
- Shingles Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Shingles Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Contact Us
Kanishk
